Patents by Inventor Steve Creighton

Steve Creighton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6544776
    Abstract: A diagnostic biochip comprising a solid support to which one or more specific nucleic acid ligands is attached in a spatially defined manner is provided. Each nucleic acid ligand binds specifically and avidly to a particular target molecule contained within a test mixture, such as a bodily fluid. Also provided are methods for the preparation of nucleic acid ligand biochips. Further, methods for the use of the nucleic acid ligand biochip in diagnosis of a medical condition and quantitative detection of a target molecule are provided.
    Type: Grant
    Filed: August 14, 2000
    Date of Patent: April 8, 2003
    Assignee: Somalogic, Inc.
    Inventors: Larry Gold, Daniel Drolet, Dominic A. Zichi, Sumedha Jayasena, Steve Creighton, Stanley Gill
  • Patent number: 6503715
    Abstract: A Nucleic acid ligand “Biochip” is disclosed, consisting of a solid support to which one or more specific Nucleic acid ligands is attached in a spatially defined manner. Each Nucleic acid ligand binds specifically and avidly to a particular Target molecule contained within a Test mixture, such as a Bodily fluid. The Target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the Test mixture with the Biochip leads to the binding of a Target molecule to its cognate Nucleic acid ligand. Binding of Target to the Nucleic acid ligand results in a detectable change at each specific location on the Biochip. The detectable change can include, but is not limited to, a change in fluorescence, or a change in a physical parameter, such as electrical conductance or refractive index, at each location on the Biochip.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: January 7, 2003
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Dan Drolet, Dom Zichi, Sumedha Jayasena, Steve Creighton, Stanley Gill
  • Patent number: 6458543
    Abstract: A Nucleic acid ligand “Biochip” is disclosed, consisting of a solid support to which one or more specific Nucleic acid ligands is attached in a spatially defined manner. Each Nucleic acid ligand binds specifically and avidly to a particular Target molecule contained within a Test mixture, such as a Bodily fluid. The Target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. In principle, the Biochip could be used to test any chemically complex mixture provided that Nucleic acid ligands to components suspected of being present in the mixture are attached to the Biochip. Thus, the Nucleic acid ligand Biochip will have a wider use in environmental testing, etc.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: October 1, 2002
    Assignee: SomaLogic, Incorporated
    Inventors: Larry Gold, Dan Drolet, Dom Zichi, Sumedha Jayasena, Steve Creighton, Stanley Gill
  • Patent number: 6242246
    Abstract: A Nucleic acid ligand “Biochip” is disclosed, consisting of a solid support to which one or more specific Nucleic acid ligands is attached in a spatially defined manner. Each Nucleic acid ligand binds specifically and avidly to a particular Target molecule contained within a Test mixture, such as a Bodily fluid The Target molecules include, but are not limited to, proteins (cellular, viral, bacterial, etc.) hormones, sugars, metabolic byproducts, cofactor, and intermediates, drugs, and toxins. Contacting the Test mixture with the Biochip leads to the binding of a Target molecule to its cognate Nucleic acid ligand. Binding of Target to the Nucleic acid ligand results in a detectable change at each specific location on the Biochip. The detectable change can include, but is not limited to, a change in fluorescence, or a change in a physical parameter, such as electrical conductance or refractive index, at each location on the Biochip.
    Type: Grant
    Filed: December 15, 1997
    Date of Patent: June 5, 2001
    Assignee: SomaLogic, Inc.
    Inventors: Larry Gold, Dan Drolet, Dom Zichi, Sumedha Jayasena, Steve Creighton, Stanley Gill